Q-omics provides the consensus-scored STRN3 profile across patient tissues and cancer cell-line models. STRN3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, STRN3 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, STRN3 RNA expression shows 21,138 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where STRN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STRN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STRN3 survival associations across molecular data types. STRN3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STRN3 RNA expression–survival associations across cancer types. High STRN3 expression shows unfavorable associations in HNSC, UVM, ACC and BLCA, but favorable associations in KIRC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for STRN3 RNA expression.
This table summarizes STRN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for STRN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STRN3 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LUAD, LUSC and CHOL. The HNSC box plot shows higher STRN3 RNA expression in tumor versus normal tissue (log2 FC = +1.248, t-test p < 0.001).
This table shows molecular features associated with STRN3 in patient tissues and cancer cell lines. In patient samples, STRN3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, STRN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
